Algert Global’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Algert Global’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-134,212	Closed	-$345K	–	394
2017 Q1	$345K	Buy	+134,212	New	+$310K	0.09%	254
2014 Q4	–	Sell	-89,044	Closed	-$541K	–	352
2014 Q3	$541K	Buy	89,044 +10,394	+13%	+$71K	0.4%	95
2014 Q2	$518K	Buy	+78,650	New	+$886K	0.33%	122

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

CRC

Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Algert Global's ECYT Position: Q2 2017 in Review

Algert Global sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2017, closing a stake of 134,212 shares — an estimated $345K sold.

Algert Global first reported a position in ECYT in Q2 2014 and held it in 3 quarters. The position peaked at $541K in Q3 2014. 75 funds tracked by Wall St. Rank hold ECYT as of Q2 2017.

Algert Global reported no remaining Endocyte, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
Algert Global sold 134,212 Endocyte, Inc. Common Stock shares in Q2 2017, an estimated $345K.
Algert Global first reported a position in Endocyte, Inc. Common Stock in Q2 2014 and held it in 3 quarters.
Algert Global's Endocyte, Inc. Common Stock position peaked at $541K in Q3 2014.
75 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2017.

Based on Algert Global's 13F filing for Q2 2017, filed 1 Aug 2017.